Agonistic Anti-CD40 Antibody Triggers an Acute Liver Crisis With Systemic Inflammation in Humanized Sickle Cell Disease Mice.
Anemia, Sickle Cell
/ blood
Animals
Antibodies
/ toxicity
CD40 Antigens
/ agonists
Cytokines
/ blood
Disease Models, Animal
Etanercept
/ pharmacology
Heart Failure
/ blood
Hemolysis
Hemopexin
/ pharmacology
Humans
Inflammation
/ blood
Inflammation Mediators
/ blood
Liver Diseases
/ blood
Mice, Transgenic
Tumor Necrosis Factor Inhibitors
/ pharmacology
Ventricular Dysfunction, Right
/ blood
CD40
liver disease (Ld)
macrophage
sickle cell anemia
vasoocclusive crisis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
11
2020
accepted:
11
01
2021
entrez:
25
3
2021
pubmed:
26
3
2021
medline:
16
9
2021
Statut:
epublish
Résumé
Sickle cell disease (SCD) is an inherited hemolytic disorder, defined by a point mutation in the β-globin gene. Stress conditions such as infection, inflammation, dehydration, and hypoxia trigger erythrocyte sickling. Sickled red blood cells (RBCs) hemolyze more rapidly, show impaired deformability, and increased adhesive properties to the endothelium. In a proinflammatory, pro-coagulative environment with preexisting endothelial dysfunction, sickled RBCs promote vascular occlusion. Hepatobiliary involvement related to the sickling process, such as an acute sickle hepatic crisis, is observed in about 10% of acute sickle cell crisis incidents. In mice, ligation of CD40 with an agonistic antibody leads to a macrophage activation in the liver, triggering a sequence of systemic inflammation, endothelial cell activation, thrombosis, and focal ischemia. We found that anti-CD40 antibody injection in sickle cell mice induces a systemic inflammatory and hemodynamic response with accelerated hemolysis, extensive vaso-occlusion, and large ischemic infarctions in the liver mimicking an acute hepatic crisis. Administration of the tumor necrosis factor-α (TNF-α) blocker, etanercept, and the heme scavenger protein, hemopexin attenuated end-organ damage. These data collectively suggest that anti-CD40 administration offers a novel acute liver crisis model in humanized sickle mice, allowing for evaluation of therapeutic proof-of-concept.
Identifiants
pubmed: 33763072
doi: 10.3389/fimmu.2021.627944
pmc: PMC7982888
doi:
Substances chimiques
Antibodies
0
CD40 Antigens
0
Cytokines
0
Inflammation Mediators
0
Tumor Necrosis Factor Inhibitors
0
Hemopexin
9013-71-2
Etanercept
OP401G7OJC
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
627944Subventions
Organisme : NHLBI NIH HHS
ID : P01 HL014985
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL125642
Pays : United States
Informations de copyright
Copyright © 2021 Yalamanoglu, Dubach, Schulthess, Ingoglia, Swindle, Humar, Schaer, Buehler, Irwin and Vallelian.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nature. 1998 Jun 4;393(6684):478-80
pubmed: 9624004
Blood. 2003 May 1;101(9):3755-6
pubmed: 12707228
J Leukoc Biol. 2000 Jan;67(1):2-17
pubmed: 10647992
Br J Haematol. 2007 Nov;139(4):612-20
pubmed: 17916103
Science. 1995 Sep 8;269(5229):1424-7
pubmed: 7544915
Pharmacol Res Perspect. 2018 Mar 30;6(2):e00392
pubmed: 29610666
Haematologica. 2015 May;100(5):611-22
pubmed: 25616571
Cytokine. 2017 Sep;97:104-107
pubmed: 28609750
Blood. 2014 Jan 16;123(3):377-90
pubmed: 24277079
Blood. 2004 Aug 1;104(3):840-6
pubmed: 15073034
N Engl J Med. 2017 Jul 20;377(3):305
pubmed: 28723338
Haematologica. 2011 Jan;96(1):24-32
pubmed: 20851863
J Clin Invest. 2000 Aug;106(3):411-20
pubmed: 10930444
Nat Rev Dis Primers. 2018 Mar 15;4:18010
pubmed: 29542687
Arterioscler Thromb Vasc Biol. 2006 Jul;26(7):1626-31
pubmed: 16601237
Clin Liver Dis. 2019 May;23(2):177-189
pubmed: 30947870
Microcirculation. 2004 Mar;11(2):129-51
pubmed: 15280088
PLoS One. 2018 Apr 25;13(4):e0196455
pubmed: 29694434
J Clin Invest. 2000 Aug;106(3):337-8
pubmed: 10930436
Hepatology. 2001 May;33(5):1021-8
pubmed: 11343226
Circ Heart Fail. 2019 Jan;12(1):e005512
pubmed: 30616360
Chest. 2016 Apr;149(4):1082-93
pubmed: 26836899
Am J Respir Crit Care Med. 2004 Mar 15;169(6):687-95
pubmed: 14684557
Free Radic Biol Med. 2015 Dec;89:931-43
pubmed: 26475040
N Engl J Med. 1997 Nov 27;337(22):1584-90
pubmed: 9371854
N Engl J Med. 1980 May 1;302(18):992-5
pubmed: 7366623
Am J Hematol. 2017 Nov;92(11):1119-1130
pubmed: 28699284
Am Fam Physician. 2000 Mar 1;61(5):1349-56, 1363-4
pubmed: 10735342
J Proteome Res. 2011 May 6;10(5):2397-408
pubmed: 21405025
Anal Biochem. 1971 Apr;40(2):450-8
pubmed: 5551554
J Clin Oncol. 2001 Jul 1;19(13):3280-7
pubmed: 11432896
Blood. 1994 Jul 15;84(2):643-9
pubmed: 7517723
J Clin Invest. 2013 Nov;123(11):4809-20
pubmed: 24084741
Drugs. 1999 Jun;57(6):945-66
pubmed: 10400407
Clin Chim Acta. 1975 Jun 2;61(2):229-32
pubmed: 1132154
Blood Adv. 2020 Jun 23;4(12):2751-2761
pubmed: 32559293
Annu Rev Pathol. 2019 Jan 24;14:263-292
pubmed: 30332562
Blood. 2010 Dec 2;116(23):5010-20
pubmed: 20798237
Blood. 2013 Feb 21;121(8):1276-84
pubmed: 23264591
J Vis Exp. 2018 Feb 12;(132):
pubmed: 29553556
Blood. 2006 Feb 15;107(4):1651-8
pubmed: 16166585
Blood. 2000 Oct 1;96(7):2451-9
pubmed: 11001897
J Clin Invest. 2020 Oct 1;130(10):5576-5590
pubmed: 32663195
Arch Intern Med. 1974 Apr;133(4):611-9
pubmed: 4818434
Mol Med. 2016 Sep;22:437-451
pubmed: 27451971
Front Physiol. 2014 Oct 28;5:415
pubmed: 25389409
Nature. 1957 Aug 17;180(4581):326-8
pubmed: 13464827
Am J Physiol Lung Cell Mol Physiol. 2018 Nov 1;315(5):L765-L774
pubmed: 30047285
Blood. 2014 Jun 12;123(24):3818-27
pubmed: 24620350
J Clin Invest. 2017 Mar 1;127(3):750-760
pubmed: 28248201
Science. 1997 Oct 31;278(5339):876-8
pubmed: 9346488
Cold Spring Harb Perspect Med. 2012 Sep 01;2(9):a011692
pubmed: 22951448